person · Reporting owner

Hung David

Disclosed activity across 6 companies

Tapewire entity: 40919
SEC CIK: 0001310880

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
ESTABLISHMENT LABS HOLDINGS INC.ESTA · Entity 4473	Director	May 26, 2020	May 27, 2020
NovoCure LtdNVCR · Entity 4494	Director	June 03, 2026	June 05, 2026
Nuvation Bio Inc.NUVB · Entity 4384	Director · PRESIDENT AND CEO · 10% owner	February 27, 2026	March 04, 2026
Sio Gene Therapies Inc.AXON · Entity 130622	Director · Principal Executive Officer	December 29, 2017	January 03, 2018

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

ESTABLISHMENT LABS HOLDINGS INC.

Report date May 26, 2020 · Filed May 27, 2020

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $18.14 · Expires 2030-05-26	Direct	10,000	Reported balance After 2020-05-26 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2020-05-26 · Grant · Acquired 10,000 · Balance 10,000 F1: The shares subject to the option vest in full on the earlier of May 26, 2021 or the day prior to the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person continuing as a service provider through such date.

Filing footnotes · ownership attribution and instrument terms

F1: The shares subject to the option vest in full on the earlier of May 26, 2021 or the day prior to the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person continuing as a service provider through such date.

NovoCure Ltd

Report date June 03, 2026 · Filed June 05, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Ordinary SharesSEC Table I · non-derivative	Direct	32,075	Reported balance After 2026-06-03 transaction · row 1 Account or security details depend on footnotes; rows are not merged. 1 source row Row 1 · 2026-06-03 · Grant · Acquired 11,610 · Balance 32,075 F1: Represents restricted stock units that are scheduled to vest 100% on the earlier of the following dates: (i) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2027 annual general meeting of shareholders.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.15 · Expires 2036-06-03	Direct	16,999	Reported balance After 2026-06-03 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2026-06-03 · Grant · Acquired 16,999 · Balance 16,999 F2: Options to buy ordinary shares will fully vest and become exercisable on the earlier of the following dates: (i) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2027 annual general meeting of shareholders.

Filing footnotes · ownership attribution and instrument terms

F1: Represents restricted stock units that are scheduled to vest 100% on the earlier of the following dates: (i) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2027 annual general meeting of shareholders.

F2: Options to buy ordinary shares will fully vest and become exercisable on the earlier of the following dates: (i) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2027 annual general meeting of shareholders.

Nuvation Bio Inc.

Report date February 27, 2026 · Filed March 04, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.91 · Expires 2036-02-26	Direct	1,995,012	Reported balance After 2026-02-27 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-02-27 · Grant · Acquired 1,995,012 · Balance 1,995,012 F1: Option vests as to 25% on the one year anniversary of 2/27/2026, and monthly thereafter over the following 36 months, subject to Reporting Person's continuous service on each such vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: Option vests as to 25% on the one year anniversary of 2/27/2026, and monthly thereafter over the following 36 months, subject to Reporting Person's continuous service on each such vesting date.

Sio Gene Therapies Inc.

Report date December 29, 2017 · Filed January 03, 2018

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.27 · Expires 2027-12-29	Direct	2,000,000	Reported balance After 2017-12-29 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2017-12-29 · Exercise / conversion · Acquired 2,000,000 · Balance 2,000,000 F1: This option is immediately exercisable, subject to a repurchase right in favor of the Issuer that lapses as the option vests. 20% of the common shares underlying the option vest on December 29, 2018, and the balance of the shares vest in a series of 16 successive equal quarterly installments thereafter, subject to the Reporting Person providing continuous service to the Issuer as of each such date, but only if the 30-consecutive day volume-weighted average closing price of the Issuer's common shares equals or exceeds $7.91 at any point during the 10-year term of the option.

Filing footnotes · ownership attribution and instrument terms

F1: This option is immediately exercisable, subject to a repurchase right in favor of the Issuer that lapses as the option vests. 20% of the common shares underlying the option vest on December 29, 2018, and the balance of the shares vest in a series of 16 successive equal quarterly installments thereafter, subject to the Reporting Person providing continuous service to the Issuer as of each such date, but only if the 30-consecutive day volume-weighted average closing price of the Issuer's common shares equals or exceeds $7.91 at any point during the 10-year term of the option.

Past disclosures · reporting ended (2)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

ARYA SCIENCES ACQUISITION CORP.

Report date July 01, 2020 · Filed July 07, 2020

Section 16 reporting ended · disclosed 2020-07-07. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Class B Ordinary SharesSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2020-07-01 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2020-07-01 · Disposition to issuer · Disposed 30,000 · Balance 0 F1: In connection with the merger of ARYA Sciences Acquisition Corp. (the "Issuer") with and into a subsidiary of Immatics N.V. ("IMTX"), and a series of related transactions (collectively, the "Business Combination"), the Class B Ordinary Shares, par value $0.0001 per share, of the Issuer held by the Reporting Person were exchanged for Ordinary Shares, nominal value EURO0.01 per share, of IMTX. Upon consummation of the Business Combination the Reporting Person is no longer subject to the reporting requirements of Section 16 with respect to the Issuer's securities.

Filing footnotes · ownership attribution and instrument terms

F1: In connection with the merger of ARYA Sciences Acquisition Corp. (the "Issuer") with and into a subsidiary of Immatics N.V. ("IMTX"), and a series of related transactions (collectively, the "Business Combination"), the Class B Ordinary Shares, par value $0.0001 per share, of the Issuer held by the Reporting Person were exchanged for Ordinary Shares, nominal value EURO0.01 per share, of IMTX. Upon consummation of the Business Combination the Reporting Person is no longer subject to the reporting requirements of Section 16 with respect to the Issuer's securities.

MEDIVATION, INC.

Report date September 28, 2016 · Filed September 30, 2016

Section 16 reporting ended · disclosed 2016-09-30. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2016-09-28 transaction · row 1 Sequence does not reconcile; account continuity is unresolved. 1 source row Row 1 · 2016-09-28 · Other · Disposed 1,470,087 · Balance 0 F1: Disposed of pursuant to an Agreement and Plan of Merger (the "Merger Agreement"), dated August 20, 2016, among the Issuer, Pfizer Inc., a Delaware corporation ("Parent"), and Montreal, Inc., a Delaware corporation and a wholly-owned subsidiary of Parent ("Purchaser"), in exchange for a cash consideration of $81.50 per share (without interest) subject to any required withholding of taxes. Pursuant to the Merger Agreement, the Purchaser merged with and into the Issuer, with the Issuer surviving as a wholly-owned subsidiary of Parent (the "Merger"). In connection with the Merger, Purchaser offered to purchase all of the outstanding shares of common stock, par value $0.01 per share of the Issuer, at a price of $81.50 per share, net to the seller in cash (without interest) but subject to any required withholding of taxes, upon the terms and conditions set forth in the offer to purchase dated August 30, 2016, and in the related letter of transmittal.
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2016-09-28 transaction · row 2 Sequence does not reconcile; account continuity is unresolved. 1 source row Row 2 · 2016-09-28 · Disposition to issuer · Disposed 94,290 · Balance 0 F1: Disposed of pursuant to an Agreement and Plan of Merger (the "Merger Agreement"), dated August 20, 2016, among the Issuer, Pfizer Inc., a Delaware corporation ("Parent"), and Montreal, Inc., a Delaware corporation and a wholly-owned subsidiary of Parent ("Purchaser"), in exchange for a cash consideration of $81.50 per share (without interest) subject to any required withholding of taxes. Pursuant to the Merger Agreement, the Purchaser merged with and into the Issuer, with the Issuer surviving as a wholly-owned subsidiary of Parent (the "Merger"). In connection with the Merger, Purchaser offered to purchase all of the outstanding shares of common stock, par value $0.01 per share of the Issuer, at a price of $81.50 per share, net to the seller in cash (without interest) but subject to any required withholding of taxes, upon the terms and conditions set forth in the offer to purchase dated August 30, 2016, and in the related letter of transmittal. F2: Represents unvested restricted stock units (the "RSUs") that were cancelled in the Merger and, in lieu of any issuance of shares in settlement of such RSUs, converted into the right to receive cash payment equal to $81.50 per share (without interest) subject to any required withholding of taxes. In connection with the Merger, vesting of the RSUs was accelerated and the RSUs became fully vested effective immediately prior to the effective time of the Merger.
Common StockSEC Table I · non-derivative	IndirectBy Trust	Reported balance After 2016-09-28 transaction · row 3 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 3 · 2016-09-28 · Other · Disposed 145,120 · Balance 0 F1: Disposed of pursuant to an Agreement and Plan of Merger (the "Merger Agreement"), dated August 20, 2016, among the Issuer, Pfizer Inc., a Delaware corporation ("Parent"), and Montreal, Inc., a Delaware corporation and a wholly-owned subsidiary of Parent ("Purchaser"), in exchange for a cash consideration of $81.50 per share (without interest) subject to any required withholding of taxes. Pursuant to the Merger Agreement, the Purchaser merged with and into the Issuer, with the Issuer surviving as a wholly-owned subsidiary of Parent (the "Merger"). In connection with the Merger, Purchaser offered to purchase all of the outstanding shares of common stock, par value $0.01 per share of the Issuer, at a price of $81.50 per share, net to the seller in cash (without interest) but subject to any required withholding of taxes, upon the terms and conditions set forth in the offer to purchase dated August 30, 2016, and in the related letter of transmittal.
Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.29 · Expires 2017-10-01	Direct	Reported balance After 2016-09-28 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2016-09-28 · Disposition to issuer · Disposed 448,888 · Balance 0 F3: This option was cancelled in the Merger in exchange for a cash payment equal to $81.50 per share (without interest) subject to any required withholding of taxes minus the per share exercise price of the option. In connection with the Merger, vesting of the option was accelerated and the option became fully vested and exercisable effective immediately prior to the effective time of the Merger.
Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.69 · Expires 2018-10-31	Direct	Reported balance After 2016-09-28 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2016-09-28 · Disposition to issuer · Disposed 366,194 · Balance 0 F3: This option was cancelled in the Merger in exchange for a cash payment equal to $81.50 per share (without interest) subject to any required withholding of taxes minus the per share exercise price of the option. In connection with the Merger, vesting of the option was accelerated and the option became fully vested and exercisable effective immediately prior to the effective time of the Merger.
Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.64 · Expires 2019-12-15	Direct	Reported balance After 2016-09-28 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2016-09-28 · Disposition to issuer · Disposed 593,750 · Balance 0 F3: This option was cancelled in the Merger in exchange for a cash payment equal to $81.50 per share (without interest) subject to any required withholding of taxes minus the per share exercise price of the option. In connection with the Merger, vesting of the option was accelerated and the option became fully vested and exercisable effective immediately prior to the effective time of the Merger.
Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.37 · Expires 2020-12-15	Direct	Reported balance After 2016-09-28 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2016-09-28 · Disposition to issuer · Disposed 400,000 · Balance 0 F3: This option was cancelled in the Merger in exchange for a cash payment equal to $81.50 per share (without interest) subject to any required withholding of taxes minus the per share exercise price of the option. In connection with the Merger, vesting of the option was accelerated and the option became fully vested and exercisable effective immediately prior to the effective time of the Merger.
Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $27.43 · Expires 2022-12-17	Direct	Reported balance After 2016-09-28 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2016-09-28 · Disposition to issuer · Disposed 310,000 · Balance 0 F3: This option was cancelled in the Merger in exchange for a cash payment equal to $81.50 per share (without interest) subject to any required withholding of taxes minus the per share exercise price of the option. In connection with the Merger, vesting of the option was accelerated and the option became fully vested and exercisable effective immediately prior to the effective time of the Merger.
Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $41.78 · Expires 2024-02-18	Direct	Reported balance After 2016-09-28 transaction · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · 2016-09-28 · Disposition to issuer · Disposed 266,000 · Balance 0 F3: This option was cancelled in the Merger in exchange for a cash payment equal to $81.50 per share (without interest) subject to any required withholding of taxes minus the per share exercise price of the option. In connection with the Merger, vesting of the option was accelerated and the option became fully vested and exercisable effective immediately prior to the effective time of the Merger.
Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $52.67 · Expires 2025-02-17	Direct	Reported balance After 2016-09-28 transaction · row 10 Instrument identity requires review; Table II rows are not merged. 1 source row Row 10 · 2016-09-28 · Disposition to issuer · Disposed 228,000 · Balance 0 F3: This option was cancelled in the Merger in exchange for a cash payment equal to $81.50 per share (without interest) subject to any required withholding of taxes minus the per share exercise price of the option. In connection with the Merger, vesting of the option was accelerated and the option became fully vested and exercisable effective immediately prior to the effective time of the Merger.
Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $35.77 · Expires 2026-02-28	Direct	Reported balance After 2016-09-28 transaction · row 11 Instrument identity requires review; Table II rows are not merged. 1 source row Row 11 · 2016-09-28 · Disposition to issuer · Disposed 205,500 · Balance 0 F3: This option was cancelled in the Merger in exchange for a cash payment equal to $81.50 per share (without interest) subject to any required withholding of taxes minus the per share exercise price of the option. In connection with the Merger, vesting of the option was accelerated and the option became fully vested and exercisable effective immediately prior to the effective time of the Merger.
Performance-Based Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 · Expires 2020-02-18	Direct	Reported balance After 2016-09-28 transaction · row 12 Instrument identity requires review; Table II rows are not merged. 1 source row Row 12 · 2016-09-28 · Disposition to issuer · Disposed 77,337 · Balance 0 F4: The number of shares subject to the performance-based restricted stock unit (the "PSUs") is based on deemed satisfaction of all applicable performance goals at the maximum levels. F5: The PSUs were cancelled in the Merger and, in lieu of any issuance of shares in settlement of such PSUs, converted into the right to receive cash payment equal to $81.50 per share (without interest) subject to any required withholding of taxes. In connection with the Merger, vesting of the PSUs was accelerated and the PSUs became fully vested effective immediately prior to the effective time of the Merger.
Stock Appreciation RightsSEC Table II · derivative / convertible security · Conversion / exercise price $12.20 · Expires 2021-12-09	Direct	Reported balance After 2016-09-28 transaction · row 13 Instrument identity requires review; Table II rows are not merged. 1 source row Row 13 · 2016-09-28 · Disposition to issuer · Disposed 534,400 · Balance 0 F6: This stock appreciation right (the "SAR") was cancelled in the Merger in exchange for a cash payment equal to $81.50 per share (without interest) subject to any required withholding of taxes minus the per share base price of the SAR.

Filing footnotes · ownership attribution and instrument terms

F1: Disposed of pursuant to an Agreement and Plan of Merger (the "Merger Agreement"), dated August 20, 2016, among the Issuer, Pfizer Inc., a Delaware corporation ("Parent"), and Montreal, Inc., a Delaware corporation and a wholly-owned subsidiary of Parent ("Purchaser"), in exchange for a cash consideration of $81.50 per share (without interest) subject to any required withholding of taxes. Pursuant to the Merger Agreement, the Purchaser merged with and into the Issuer, with the Issuer surviving as a wholly-owned subsidiary of Parent (the "Merger"). In connection with the Merger, Purchaser offered to purchase all of the outstanding shares of common stock, par value $0.01 per share of the Issuer, at a price of $81.50 per share, net to the seller in cash (without interest) but subject to any required withholding of taxes, upon the terms and conditions set forth in the offer to purchase dated August 30, 2016, and in the related letter of transmittal.

F2: Represents unvested restricted stock units (the "RSUs") that were cancelled in the Merger and, in lieu of any issuance of shares in settlement of such RSUs, converted into the right to receive cash payment equal to $81.50 per share (without interest) subject to any required withholding of taxes. In connection with the Merger, vesting of the RSUs was accelerated and the RSUs became fully vested effective immediately prior to the effective time of the Merger.

F3: This option was cancelled in the Merger in exchange for a cash payment equal to $81.50 per share (without interest) subject to any required withholding of taxes minus the per share exercise price of the option. In connection with the Merger, vesting of the option was accelerated and the option became fully vested and exercisable effective immediately prior to the effective time of the Merger.

F4: The number of shares subject to the performance-based restricted stock unit (the "PSUs") is based on deemed satisfaction of all applicable performance goals at the maximum levels.

F5: The PSUs were cancelled in the Merger and, in lieu of any issuance of shares in settlement of such PSUs, converted into the right to receive cash payment equal to $81.50 per share (without interest) subject to any required withholding of taxes. In connection with the Merger, vesting of the PSUs was accelerated and the PSUs became fully vested effective immediately prior to the effective time of the Merger.

F6: This stock appreciation right (the "SAR") was cancelled in the Merger in exchange for a cash payment equal to $81.50 per share (without interest) subject to any required withholding of taxes minus the per share base price of the SAR.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
June 03, 2026 Filed Jun 5, 2026 20:26 UTC	NovoCure Ltd NVCR · Entity 4494	GrantStock Option (Right to Buy) · Derivative	16,999	$0.00 Strike: $16.15	$0.00	Disclosure SEC source: 0001310880-26-000006 · primarydocument.xml · derivative · entry 2 Hung David · CIK 0001310880 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,999 Underlying: Ordinary Shares · 16,999 shares Expires 2036-06-03 F2 · derivative.exercise_date: Options to buy ordinary shares will fully vest and become exercisable on the earlier of the following dates: (i) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2027 annual general meeting of shareholders. Read SEC document
June 03, 2026 Filed Jun 5, 2026 20:26 UTC	NovoCure Ltd NVCR · Entity 4494	GrantOrdinary Shares	11,610	$0.00	$0.00	Disclosure SEC source: 0001310880-26-000006 · primarydocument.xml · nonDerivative · entry 1 Hung David · CIK 0001310880 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,075 F1 · security: Represents restricted stock units that are scheduled to vest 100% on the earlier of the following dates: (i) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2027 annual general meeting of shareholders. Read SEC document
June 02, 2026 Filed Jun 3, 2026 20:52 UTC	NovoCure Ltd NVCR · Entity 4494	SaleOrdinary Shares	2,945	$15.77	$46,444.71	Disclosure SEC source: 0001310880-26-000005 · primarydocument.xml · nonDerivative · entry 1 Hung David · CIK 0001310880 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,465 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · price: This transaction was executed in multiple trades at prices ranging from $15.65 USD to $15.88 USD; the price reported above reflects the weighted average sale price. Read SEC document
February 27, 2026 Filed Mar 4, 2026 00:50 UTC	Nuvation Bio Inc. NUVB · Entity 4384	GrantStock Option (Right to Buy) · Derivative	1,995,012	$0.00 Strike: $5.91	$0.00	Disclosure SEC source: 0001310880-26-000003 · form4-03042026_120352.xml · derivative · entry 1 Hung David · CIK 0001310880 · Director · PRESIDENT AND CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,995,012 Underlying: Class A Common Stock · 1,995,012 shares Expires 2036-02-26 F1 · derivative.exercise_date: Option vests as to 25% on the one year anniversary of 2/27/2026, and monthly thereafter over the following 36 months, subject to Reporting Person's continuous service on each such vesting date. Read SEC document
June 16, 2025 Filed Jun 18, 2025 20:05 UTC	Nuvation Bio Inc. NUVB · Entity 4384	PurchaseClass A Common Stock	500,000	$1.79	$893,500.00	Disclosure SEC source: 0001415889-25-017656 · form4-06182025_040601.xml · nonDerivative · entry 1 Hung David · CIK 0001310880 · Director · PRESIDENT AND CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 59,281,054 F1 · price: ) The price reported is a weighted-average price. These shares were purchased in multiple transactions at prices ranging from $1.64 to $1.88, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price. Read SEC document
June 04, 2025 Filed Jun 6, 2025 20:14 UTC	NovoCure Ltd NVCR · Entity 4494	GrantStock Option (Right to Buy) · Derivative	16,697	$0.00 Strike: $16.72	$0.00	Disclosure SEC source: 0001562180-25-004556 · primarydocument.xml · derivative · entry 2 Hung David · CIK 0001310880 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,697 Underlying: Ordinary Shares · 16,697 shares Expires 2035-06-04 F2 · derivative.exercise_date: Options to buy ordinary shares will fully vest and become exercisable on the earlier of the following dates: (i) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2026 annual general meeting of shareholders. Read SEC document
June 04, 2025 Filed Jun 6, 2025 20:14 UTC	NovoCure Ltd NVCR · Entity 4494	GrantOrdinary Shares	11,215	$0.00	$0.00	Disclosure SEC source: 0001562180-25-004556 · primarydocument.xml · nonDerivative · entry 1 Hung David · CIK 0001310880 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,410 F1 · security: Represents restricted stock units that are scheduled to vest 100% on the earlier of the following dates: (i) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2026 annual general meeting of shareholders. Read SEC document
June 03, 2025 Filed Jun 4, 2025 20:11 UTC	NovoCure Ltd NVCR · Entity 4494	SaleOrdinary Shares	999	$17.30	$17,279.50	Disclosure SEC source: 0001562180-25-004428 · primarydocument.xml · nonDerivative · entry 1 Hung David · CIK 0001310880 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,195 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · price: This transaction was executed in multiple trades at prices ranging from $17.1025 USD to $17.50 USD; the price reported above reflects the weighted average sale price. Read SEC document
April 07, 2025 Filed Apr 9, 2025 01:30 UTC	Nuvation Bio Inc. NUVB · Entity 4384	PurchaseClass A Common Stock	300,000	$1.63	$487,500.00	Disclosure SEC source: 0001415889-25-010446 · form4-04092025_010447.xml · nonDerivative · entry 2 Hung David · CIK 0001310880 · Director · PRESIDENT AND CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 58,781,054 F2 · price: ) The price reported is a weighted-average price. These shares were purchased in multiple transactions at prices ranging from $1.54 to $1.78, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price. Read SEC document
April 04, 2025 Filed Apr 9, 2025 01:30 UTC	Nuvation Bio Inc. NUVB · Entity 4384	PurchaseClass A Common Stock	200,000	$1.66	$332,720.00	Disclosure SEC source: 0001415889-25-010446 · form4-04092025_010447.xml · nonDerivative · entry 1 Hung David · CIK 0001310880 · Director · PRESIDENT AND CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 58,481,054 F1 · price: The price reported is a weighted-average price. These shares were purchased in multiple transactions at prices ranging from $1.6499 to $1.6699, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price. Read SEC document
February 28, 2025 Filed Mar 4, 2025 23:33 UTC	Nuvation Bio Inc. NUVB · Entity 4384	GrantStock Option (Right to Buy) · Derivative	2,000,000	$0.00 Strike: $1.97	$0.00	Disclosure SEC source: 0001415889-25-006692 · form4-03042025_110312.xml · derivative · entry 1 Hung David · CIK 0001310880 · Director · PRESIDENT AND CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,000,000 Underlying: Class B Common Stock · 2,000,000 shares Expires 2035-02-27 F1 · derivative.exercise_date: Option vests as to 25% on the one year anniversary of 2/28/2025, and monthly thereafter over the following 36 months, subject to Reporting Person's continuous service on each such vesting date. Read SEC document
June 05, 2024 Filed Jun 6, 2024 21:55 UTC	NovoCure Ltd NVCR · Entity 4494	GrantStock Option (Right to Buy) · Derivative	6,229	$0.00 Strike: $23.13	$0.00	Disclosure SEC source: 0001562180-24-004768 · primarydocument.xml · derivative · entry 2 Hung David · CIK 0001310880 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,229 Underlying: Ordinary Shares · 6,229 shares Expires 2034-06-04 F2 · derivative.exercise_date: Options to buy 6,229 ordinary shares will fully vest and become exercisable on the earlier of the following dates: (i) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2025 annual general meeting of shareholders. Read SEC document
June 05, 2024 Filed Jun 6, 2024 21:55 UTC	NovoCure Ltd NVCR · Entity 4494	GrantRestricted Stock Units	4,053	$0.00	$0.00	Disclosure SEC source: 0001562180-24-004768 · primarydocument.xml · nonDerivative · entry 1 Hung David · CIK 0001310880 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,194 F1 · shares: These restricted stock units are scheduled to vest 100% on the earlier of the following dates: (i) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2025 annual general meeting of shareholders. Read SEC document
February 29, 2024 Filed Mar 4, 2024 21:20 UTC	Nuvation Bio Inc. NUVB · Entity 4384	GrantStock Option (Right to Buy) · Derivative	2,000,000	$0.00 Strike: $1.87	$0.00	Disclosure SEC source: 0001415889-24-006276 · form4-03042024_090313.xml · derivative · entry 1 Hung David · CIK 0001310880 · Director · PRESIDENT AND CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,000,000 Underlying: Class A Common Stock · 2,000,000 shares Expires 2034-02-27 F1 · derivative.exercise_date: Option vests as to 25% on the one year anniversary of 2/29/2024, and monthly thereafter over the following 36 months, subject to Reporting Person's continuous service on each such vesting date. Read SEC document
June 07, 2023 Filed Jun 9, 2023 20:04 UTC	NovoCure Ltd NVCR · Entity 4494	GrantStock Option (Right to Buy) · Derivative	12,554	$0.00 Strike: $48.66	$0.00	Disclosure SEC source: 0001562180-23-005015 · primarydocument.xml · derivative · entry 1 Hung David · CIK 0001310880 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,554 Underlying: Ordinary Shares · 12,554 shares Expires 2033-06-06 F1 · derivative.exercise_date: Options to buy 12,554 ordinary shares will fully vest and become exercisable on the earlier of the following dates: (i) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2024 annual general meeting of shareholders. Read SEC document
February 28, 2023 Filed Mar 2, 2023 23:01 UTC	Nuvation Bio Inc. NUVB · Entity 4384	GrantStock Option (Right to Buy) · Derivative	2,500,000	$0.00 Strike: $1.94	$0.00	Disclosure SEC source: 0001209191-23-014890 · doc4.xml · derivative · entry 2 Hung David · CIK 0001310880 · Director · President and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,500,000 Underlying: Class A Common Stock · 2,500,000 shares Expires 2033-02-27 F3 · derivative.exercise_date: Option vests as to 25% on the one year anniversary of 2/28/2023, and monthly thereafter over the following 36 months, subject to Reporting Person's continuous service on each such vesting date. Read SEC document
June 08, 2022 Filed Jun 10, 2022 20:11 UTC	NovoCure Ltd NVCR · Entity 4494	GrantOptions to Buy Ordinary Shares · Derivative	4,350	$0.00 Strike: $77.25	$0.00	Disclosure SEC source: 0001645113-22-000054 · wf-form4_165489189409829.xml · derivative · entry 2 Hung David · CIK 0001310880 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,350 Underlying: Ordinary Shares · 4,350 shares Expires 2032-06-08 F2 · derivative.exercise_date: Options to buy 4,350 ordinary shares will fully vest and become exercisable on the earlier of the following dates: (i) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2023 annual general meeting of shareholders. Read SEC document
June 08, 2022 Filed Jun 10, 2022 20:11 UTC	NovoCure Ltd NVCR · Entity 4494	GrantRestricted Stock Units	2,427	$0.00	$0.00	Disclosure SEC source: 0001645113-22-000054 · wf-form4_165489189409829.xml · nonDerivative · entry 1 Hung David · CIK 0001310880 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,141 F1 · shares: These restricted stock units are scheduled to vest 100% on the earlier of the following dates: (1) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2023 annual general meeting of shareholders. Read SEC document
February 28, 2022 Filed Mar 2, 2022 19:29 UTC	Nuvation Bio Inc. NUVB · Entity 4384	GrantStock Option (Right to Buy) · Derivative	2,000,000	$0.00 Strike: $5.06	$0.00	Disclosure SEC source: 0001209191-22-014581 · doc4.xml · derivative · entry 2 Hung David · CIK 0001310880 · Director · President and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,000,000 Underlying: Class A Common Stock · 2,000,000 shares Expires 2032-02-27 F2 · derivative.exercise_date: Option vests as to 25% on the one year anniversary of 2/28/2022, and monthly thereafter over the following 36 months, subject to Reporting Person's continuous service on each such vesting date. Read SEC document
June 09, 2021 Filed Jun 11, 2021 20:19 UTC	NovoCure Ltd NVCR · Entity 4494	GrantOptions to Buy Ordinary Shares · Derivative	1,499	$0.00 Strike: $211.89	$0.00	Disclosure SEC source: 0001645113-21-000075 · wf-form4_162344277249172.xml · derivative · entry 2 Hung David · CIK 0001310880 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,499 Underlying: Ordinary Shares · 1,499 shares Expires 2031-06-09 F2 · derivative.exercise_date: Options to buy 1,499 ordinary shares will fully vest and become exercisable on the earlier of the following dates: (i) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2022 annual general meeting of shareholders. Read SEC document
June 09, 2021 Filed Jun 11, 2021 20:19 UTC	NovoCure Ltd NVCR · Entity 4494	GrantRestricted Stock Units	814	$0.00	$0.00	Disclosure SEC source: 0001645113-21-000075 · wf-form4_162344277249172.xml · nonDerivative · entry 1 Hung David · CIK 0001310880 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,714 F1 · shares: These restricted stock units are scheduled to vest 100% on the earlier of the following dates: (1) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2022 annual general meeting of shareholders. Read SEC document
March 09, 2021 Filed Mar 11, 2021 21:35 UTC	Nuvation Bio Inc. NUVB · Entity 4384	GrantStock Option (Right to Buy) · Derivative	224,760	$0.00 Strike: $12.66	$0.00	Disclosure SEC source: 0001209191-21-019786 · doc4.xml · derivative · entry 2 Hung David · CIK 0001310880 · Director · President and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 224,760 Underlying: Common Stock · 224,760 shares Expires 2031-03-08 F2 · derivative.exercise_date: Option vests upon the achievement of certain performance goals, including market-price goals, through the fifth anniversary of March 9, 2021, subject to Reporting Person's continuous service on each such vesting date. Read SEC document
March 09, 2021 Filed Mar 11, 2021 21:35 UTC	Nuvation Bio Inc. NUVB · Entity 4384	GrantStock Option (Right to Buy) · Derivative	165,465	$0.00 Strike: $12.66	$0.00	Disclosure SEC source: 0001209191-21-019786 · doc4.xml · derivative · entry 1 Hung David · CIK 0001310880 · Director · President and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 165,465 Underlying: Common Stock · 165,465 shares Expires 2031-03-08 F1 · derivative.exercise_date: Option vests as to 25% on the one year anniversary of 3/9/2021, and monthly thereafter over the following 36 months, subject to Reporting Person's continuous service on each such vesting date. Read SEC document
March 02, 2021 Filed Mar 2, 2023 23:01 UTC	Nuvation Bio Inc. NUVB · Entity 4384	OtherClass A Common Stock	368,408	$0.00	$0.00	Disclosure SEC source: 0001209191-23-014890 · doc4.xml · nonDerivative · entry 1 Hung David · CIK 0001310880 · Director · President and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,281,054 F1 · shares: On March 2, 2021, the Reporting Person surrendered 368,408 shares of the Issuer's Class A Common Stock in connection with the satisfaction of the Issuer's obligations to GiraFpharma LLC. F2 · balance_after: Includes 2,661 shares acquired on May 19, 2022 and 1 share acquired on November 18, 2022 under the Issuer's 2021 Employee Stock Purchase Plan. Read SEC document
February 10, 2021 Filed Feb 12, 2021 22:45 UTC	Nuvation Bio Inc. NUVB · Entity 4384	GrantClass B Common Stock · Derivative	1,000,000	$0.00	$0.00	Disclosure SEC source: 0001209191-21-010326 · doc4.xml · derivative · entry 3 Hung David · CIK 0001310880 · Director · President and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,000,000 Underlying: Class A Common Stock · 1,000,000 shares Expires not disclosed F3 · derivative.exercise_price: Each share of Class B Common Stock is convertible at any time at the option of the Reporting Person into one share of Class A Common Stock and has no expiration date. Each share of Class B Common Stock will convert automatically into one share of Class A Common Stock upon the earliest of: (i) any transfer, whether or not for value, except for certain "Permitted Transfers" as defined in the Issuer's amended and restated certificate of incorporation, (ii) the death of the Reporting Person in the case of shares held directly or in a trustee capacity, and (iii) the tenth anniversary of the Issuer's initial public offering of its Class A Common Stock. F1 · kind: Received pursuant to the Agreement and Plan of Merger, dated as of October 20, 2020, by and among Panacea Acquisition Corp. ("Panacea") and Panacea Merger Subsidiary Corp., a direct, wholly-owned subsidiary of Panacea ("Merger Sub"), and Nuvation Bio Inc. ("Legacy Nuvation") pursuant to which, as a result of a merger between Legacy Nuvation and Merger Sub, Legacy Nuvation became a direct, wholly-owned subsidiary of Panacea, which subsequently changed its name to Nuvation Bio Inc. (the "Issuer"). F3 · derivative.exercise_date: Each share of Class B Common Stock is convertible at any time at the option of the Reporting Person into one share of Class A Common Stock and has no expiration date. Each share of Class B Common Stock will convert automatically into one share of Class A Common Stock upon the earliest of: (i) any transfer, whether or not for value, except for certain "Permitted Transfers" as defined in the Issuer's amended and restated certificate of incorporation, (ii) the death of the Reporting Person in the case of shares held directly or in a trustee capacity, and (iii) the tenth anniversary of the Issuer's initial public offering of its Class A Common Stock. F3 · derivative.expiration_date: Each share of Class B Common Stock is convertible at any time at the option of the Reporting Person into one share of Class A Common Stock and has no expiration date. Each share of Class B Common Stock will convert automatically into one share of Class A Common Stock upon the earliest of: (i) any transfer, whether or not for value, except for certain "Permitted Transfers" as defined in the Issuer's amended and restated certificate of incorporation, (ii) the death of the Reporting Person in the case of shares held directly or in a trustee capacity, and (iii) the tenth anniversary of the Issuer's initial public offering of its Class A Common Stock. Read SEC document
February 10, 2021 Filed Feb 12, 2021 22:45 UTC	Nuvation Bio Inc. NUVB · Entity 4384	GrantClass A Common Stock	2,000,000	$10.00	$20,000,000.00	Disclosure SEC source: 0001209191-21-010326 · doc4.xml · nonDerivative · entry 2 Hung David · CIK 0001310880 · Director · President and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,645,012 F2 · shares: On October 20, 2020, the Issuer entered into subscription agreements (the "Subscription Agreements") with certain investors (the "PIPE Investors") pursuant to which such investors agreed to purchase, immediately prior to the closing of the Business Combination, as defined herein, an aggregate of $476,550,000 of the Issuer's shares of Class A Common Stock at a price of $10.00 per share, or an aggregate of 47,655,000 shares of Class A Common Stock. The Reporting Person is among the PIPE Investors. Read SEC document
February 10, 2021 Filed Feb 12, 2021 22:45 UTC	Nuvation Bio Inc. NUVB · Entity 4384	GrantClass A Common Stock	56,645,012	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-21-010326 · doc4.xml · nonDerivative · entry 1 Hung David · CIK 0001310880 · Director · President and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,645,012 F1 · price: Received pursuant to the Agreement and Plan of Merger, dated as of October 20, 2020, by and among Panacea Acquisition Corp. ("Panacea") and Panacea Merger Subsidiary Corp., a direct, wholly-owned subsidiary of Panacea ("Merger Sub"), and Nuvation Bio Inc. ("Legacy Nuvation") pursuant to which, as a result of a merger between Legacy Nuvation and Merger Sub, Legacy Nuvation became a direct, wholly-owned subsidiary of Panacea, which subsequently changed its name to Nuvation Bio Inc. (the "Issuer"). Read SEC document
July 01, 2020 Filed Jul 7, 2020 01:53 UTC	ARYA SCIENCES ACQUISITION CORP. ARYA · Entity 147975	Disposition to issuerClass B Ordinary Shares · Derivative	30,000	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-20-018573 · doc4.xml · derivative · entry 1 Hung David · CIK 0001310880 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class A Ordinary Shares · 30,000 shares Expires not disclosed F1 · derivative.exercise_price: In connection with the merger of ARYA Sciences Acquisition Corp. (the "Issuer") with and into a subsidiary of Immatics N.V. ("IMTX"), and a series of related transactions (collectively, the "Business Combination"), the Class B Ordinary Shares, par value $0.0001 per share, of the Issuer held by the Reporting Person were exchanged for Ordinary Shares, nominal value EURO0.01 per share, of IMTX. Upon consummation of the Business Combination the Reporting Person is no longer subject to the reporting requirements of Section 16 with respect to the Issuer's securities. F1 · price: In connection with the merger of ARYA Sciences Acquisition Corp. (the "Issuer") with and into a subsidiary of Immatics N.V. ("IMTX"), and a series of related transactions (collectively, the "Business Combination"), the Class B Ordinary Shares, par value $0.0001 per share, of the Issuer held by the Reporting Person were exchanged for Ordinary Shares, nominal value EURO0.01 per share, of IMTX. Upon consummation of the Business Combination the Reporting Person is no longer subject to the reporting requirements of Section 16 with respect to the Issuer's securities. F1 · derivative.exercise_date: In connection with the merger of ARYA Sciences Acquisition Corp. (the "Issuer") with and into a subsidiary of Immatics N.V. ("IMTX"), and a series of related transactions (collectively, the "Business Combination"), the Class B Ordinary Shares, par value $0.0001 per share, of the Issuer held by the Reporting Person were exchanged for Ordinary Shares, nominal value EURO0.01 per share, of IMTX. Upon consummation of the Business Combination the Reporting Person is no longer subject to the reporting requirements of Section 16 with respect to the Issuer's securities. F1 · derivative.expiration_date: In connection with the merger of ARYA Sciences Acquisition Corp. (the "Issuer") with and into a subsidiary of Immatics N.V. ("IMTX"), and a series of related transactions (collectively, the "Business Combination"), the Class B Ordinary Shares, par value $0.0001 per share, of the Issuer held by the Reporting Person were exchanged for Ordinary Shares, nominal value EURO0.01 per share, of IMTX. Upon consummation of the Business Combination the Reporting Person is no longer subject to the reporting requirements of Section 16 with respect to the Issuer's securities. Read SEC document
June 10, 2020 Filed Jun 12, 2020 22:07 UTC	NovoCure Ltd NVCR · Entity 4494	GrantOptions to Buy Ordinary Shares · Derivative	5,101	$0.00 Strike: $67.89	$0.00	Disclosure SEC source: 0001645113-20-000087 · wf-form4_159199964610645.xml · derivative · entry 2 Hung David · CIK 0001310880 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,101 Underlying: Ordinary Shares · 5,101 shares Expires 2030-06-10 F2 · derivative.exercise_date: Options to buy 5,101 ordinary shares will fully vest and become exercisable on the earlier of the following dates: (i) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2021 annual general meeting of shareholders. Read SEC document
June 10, 2020 Filed Jun 12, 2020 22:07 UTC	NovoCure Ltd NVCR · Entity 4494	GrantRestricted Stock Units	2,541	$0.00	$0.00	Disclosure SEC source: 0001645113-20-000087 · wf-form4_159199964610645.xml · nonDerivative · entry 1 Hung David · CIK 0001310880 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,900 F1 · shares: These restricted stock units are scheduled to vest 100% on the earlier of the following dates: (1) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2021 annual general meeting of shareholders. Read SEC document
May 26, 2020 Filed May 27, 2020 20:42 UTC	ESTABLISHMENT LABS HOLDINGS INC. ESTA · Entity 4473	GrantStock Option (Right to buy) · Derivative	10,000	$0.00 Strike: $18.14	$0.00	Disclosure SEC source: 0001628280-20-008467 · wf-form4_159061215745964.xml · derivative · entry 1 Hung David · CIK 0001310880 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Shares · 10,000 shares Expires 2030-05-26 F1 · derivative.exercise_date: The shares subject to the option vest in full on the earlier of May 26, 2021 or the day prior to the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person continuing as a service provider through such date. Read SEC document
June 03, 2019 Filed Jun 5, 2019 20:37 UTC	ESTABLISHMENT LABS HOLDINGS INC. ESTA · Entity 4473	GrantStock Option (Right to buy) · Derivative	10,000	$0.00 Strike: $23.05	$0.00	Disclosure SEC source: 0001628280-19-007590 · wf-form4_155976701181511.xml · derivative · entry 1 Hung David · CIK 0001310880 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Shares · 10,000 shares Expires 2029-06-03 F1 · derivative.exercise_date: The shares subject to the option vest in full on the earlier of June 3, 2020 or the day prior to the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person continuing as a service provider through such date. Read SEC document
May 22, 2019 Filed May 24, 2019 20:24 UTC	NovoCure Ltd NVCR · Entity 4494	GrantOptions to Buy Ordinary Shares · Derivative	6,340	$0.00 Strike: $51.36	$0.00	Disclosure SEC source: 0001209191-19-032714 · doc4.xml · derivative · entry 2 Hung David · CIK 0001310880 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,340 Underlying: Ordinary Shares · 6,340 shares Expires 2029-05-22 F2 · derivative.exercise_date: Options to buy 6,340 ordinary shares will fully vest and become exercisable on the earlier of the following dates: (i) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2020 annual general meeting of shareholders. Read SEC document
May 22, 2019 Filed May 24, 2019 20:24 UTC	NovoCure Ltd NVCR · Entity 4494	GrantRestricted Stock Units	3,359	$0.00	$0.00	Disclosure SEC source: 0001209191-19-032714 · doc4.xml · nonDerivative · entry 1 Hung David · CIK 0001310880 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,359 F1 · shares: These restricted stock units are scheduled to vest 100% on the earlier of the following dates: (i) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2020 annual general meeting of shareholders. Read SEC document
May 31, 2018 Filed Jun 5, 2018 01:42 UTC	NovoCure Ltd NVCR · Entity 4494	GrantOptions to Buy Ordinary Shares · Derivative	45,137	$0.00 Strike: $31.45	$0.00	Disclosure SEC source: 0001209191-18-035427 · doc4.xml · derivative · entry 1 Hung David · CIK 0001310880 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,137 Underlying: Ordinary Shares · 45,137 shares Expires 2028-05-31 F1 · derivative.exercise_date: This stock option will vest in equal parts on the earlier of each of the following dates: (i) the first, second and third anniversary of the grant date and (ii) the day immediately preceding of the Company's 2019, 2020 and 2021 annual general meeting of shareholders, respectively. Read SEC document
December 29, 2017 Filed Jan 3, 2018 13:48 UTC	Sio Gene Therapies Inc. AXON · Entity 130622	Exercise / conversionStock Option (right to buy) · Derivative	2,000,000	$0.00 Strike: $5.27	$0.00	Disclosure SEC source: 0001104659-18-000371 · a4.xml · derivative · entry 1 Hung David · CIK 0001310880 · Director · Principal Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,000,000 Underlying: Common Stock · 2,000,000 shares Expires 2027-12-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: This option is immediately exercisable, subject to a repurchase right in favor of the Issuer that lapses as the option vests. 20% of the common shares underlying the option vest on December 29, 2018, and the balance of the shares vest in a series of 16 successive equal quarterly installments thereafter, subject to the Reporting Person providing continuous service to the Issuer as of each such date, but only if the 30-consecutive day volume-weighted average closing price of the Issuer's common shares equals or exceeds $7.91 at any point during the 10-year term of the option. Read SEC document
April 17, 2017 Filed Apr 19, 2017 20:06 UTC	Sio Gene Therapies Inc. AXON · Entity 130622	PurchaseCommon Shares	539,375	$18.54	$10,000,012.50	Disclosure SEC source: 0001209191-17-027436 · doc4.xml · nonDerivative · entry 1 Hung David · CIK 0001310880 · Director · Principal Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 539,375 Read SEC document
April 07, 2017 Filed Apr 11, 2017 21:55 UTC	Sio Gene Therapies Inc. AXON · Entity 130622	GrantEmployee Stock Option (Right to Buy) · Derivative	2,000,000	$0.00 Strike: $15.13	$0.00	Disclosure SEC source: 0001209191-17-026601 · doc4.xml · derivative · entry 2 Hung David · CIK 0001310880 · Director · Principal Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,000,000 Underlying: Common Shares · 2,000,000 shares Expires 2027-04-07 F2 · derivative.exercise_date: This option is immediately exercisable, subject to a repurchase right in favor of the Issuer that lapses as the option vests. 20% of the common shares underlying the option vest on April 7, 2018, and the balance of the shares vest in a series of 16 successive equal quarterly installments thereafter, subject to the Reporting Person providing continuous service to the Issuer as of each such date, but only if the 30-consecutive day volume-weighted average closing price of the Issuer's common shares equals or exceeds $100.00 per common share at any point during the 10-year term of the option. F3 · derivative.exercise_date: In the event that specified results from a clinical trial being conducted by the Issuer are not met by December 31, 2017, then the $100.00 per common share price referred to in footnote (2) will be reduced to $15.00 per common share. Subject to the achievement of the volume-weighted average closing price condition described herein, vesting is subject to acceleration in specified circumstances, including a change in control of the Issuer or the Reporting Person's termination without cause or resignation for good reason. Read SEC document
April 07, 2017 Filed Apr 11, 2017 21:55 UTC	Sio Gene Therapies Inc. AXON · Entity 130622	GrantEmployee Stock Option (Right to Buy) · Derivative	2,000,000	$0.00 Strike: $15.13	$0.00	Disclosure SEC source: 0001209191-17-026601 · doc4.xml · derivative · entry 1 Hung David · CIK 0001310880 · Director · Principal Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,000,000 Underlying: Common Shares · 2,000,000 shares Expires 2027-04-07 F1 · derivative.exercise_date: This option is immediately exercisable, subject to a repurchase right in favor of the Issuer that lapses as the option vests. 20% of the common shares underlying the option vest on April 7, 2018, and the balance of the common shares vest in a series of 16 successive equal quarterly installments thereafter, subject to the Reporting Person providing continuous service to the Issuer as of each such date. Vesting is subject to acceleration in specified circumstances, including a change in control of the Issuer or the Reporting Person's termination without cause or resignation for good reason. Read SEC document
September 28, 2016 Filed Sep 30, 2016 17:45 UTC	MEDIVATION, INC. MDVN · Entity 181987	Disposition to issuerStock Appreciation Rights · Derivative	534,400	Not disclosed Strike: $12.20	Not disclosed	Disclosure SEC source: 0001209191-16-143381 · doc4.xml · derivative · entry 13 Hung David · CIK 0001310880 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 534,400 shares Expires 2021-12-09 F6 · price: This stock appreciation right (the "SAR") was cancelled in the Merger in exchange for a cash payment equal to $81.50 per share (without interest) subject to any required withholding of taxes minus the per share base price of the SAR. F6 · derivative.exercise_date: This stock appreciation right (the "SAR") was cancelled in the Merger in exchange for a cash payment equal to $81.50 per share (without interest) subject to any required withholding of taxes minus the per share base price of the SAR. Read SEC document
September 28, 2016 Filed Sep 30, 2016 17:45 UTC	MEDIVATION, INC. MDVN · Entity 181987	Disposition to issuerPerformance-Based Restricted Stock Units · Derivative	77,337	Not disclosed Strike: $0.00	Not disclosed	Disclosure SEC source: 0001209191-16-143381 · doc4.xml · derivative · entry 12 Hung David · CIK 0001310880 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 77,337 shares Expires 2020-02-18 F4 · shares: The number of shares subject to the performance-based restricted stock unit (the "PSUs") is based on deemed satisfaction of all applicable performance goals at the maximum levels. F5 · price: The PSUs were cancelled in the Merger and, in lieu of any issuance of shares in settlement of such PSUs, converted into the right to receive cash payment equal to $81.50 per share (without interest) subject to any required withholding of taxes. In connection with the Merger, vesting of the PSUs was accelerated and the PSUs became fully vested effective immediately prior to the effective time of the Merger. F5 · derivative.exercise_date: The PSUs were cancelled in the Merger and, in lieu of any issuance of shares in settlement of such PSUs, converted into the right to receive cash payment equal to $81.50 per share (without interest) subject to any required withholding of taxes. In connection with the Merger, vesting of the PSUs was accelerated and the PSUs became fully vested effective immediately prior to the effective time of the Merger. F4 · derivative.underlying_shares: The number of shares subject to the performance-based restricted stock unit (the "PSUs") is based on deemed satisfaction of all applicable performance goals at the maximum levels. Read SEC document
September 28, 2016 Filed Sep 30, 2016 17:45 UTC	MEDIVATION, INC. MDVN · Entity 181987	Disposition to issuerNon-Qualified Stock Option (right to buy) · Derivative	205,500	Not disclosed Strike: $35.77	Not disclosed	Disclosure SEC source: 0001209191-16-143381 · doc4.xml · derivative · entry 11 Hung David · CIK 0001310880 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 205,500 shares Expires 2026-02-28 F3 · price: This option was cancelled in the Merger in exchange for a cash payment equal to $81.50 per share (without interest) subject to any required withholding of taxes minus the per share exercise price of the option. In connection with the Merger, vesting of the option was accelerated and the option became fully vested and exercisable effective immediately prior to the effective time of the Merger. F3 · derivative.exercise_date: This option was cancelled in the Merger in exchange for a cash payment equal to $81.50 per share (without interest) subject to any required withholding of taxes minus the per share exercise price of the option. In connection with the Merger, vesting of the option was accelerated and the option became fully vested and exercisable effective immediately prior to the effective time of the Merger. Read SEC document
September 28, 2016 Filed Sep 30, 2016 17:45 UTC	MEDIVATION, INC. MDVN · Entity 181987	Disposition to issuerNon-Qualified Stock Option (right to buy) · Derivative	228,000	Not disclosed Strike: $52.67	Not disclosed	Disclosure SEC source: 0001209191-16-143381 · doc4.xml · derivative · entry 10 Hung David · CIK 0001310880 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 228,000 shares Expires 2025-02-17 F3 · price: This option was cancelled in the Merger in exchange for a cash payment equal to $81.50 per share (without interest) subject to any required withholding of taxes minus the per share exercise price of the option. In connection with the Merger, vesting of the option was accelerated and the option became fully vested and exercisable effective immediately prior to the effective time of the Merger. F3 · derivative.exercise_date: This option was cancelled in the Merger in exchange for a cash payment equal to $81.50 per share (without interest) subject to any required withholding of taxes minus the per share exercise price of the option. In connection with the Merger, vesting of the option was accelerated and the option became fully vested and exercisable effective immediately prior to the effective time of the Merger. Read SEC document
September 28, 2016 Filed Sep 30, 2016 17:45 UTC	MEDIVATION, INC. MDVN · Entity 181987	Disposition to issuerNon-Qualified Stock Option (right to buy) · Derivative	266,000	Not disclosed Strike: $41.78	Not disclosed	Disclosure SEC source: 0001209191-16-143381 · doc4.xml · derivative · entry 9 Hung David · CIK 0001310880 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 266,000 shares Expires 2024-02-18 F3 · price: This option was cancelled in the Merger in exchange for a cash payment equal to $81.50 per share (without interest) subject to any required withholding of taxes minus the per share exercise price of the option. In connection with the Merger, vesting of the option was accelerated and the option became fully vested and exercisable effective immediately prior to the effective time of the Merger. F3 · derivative.exercise_date: This option was cancelled in the Merger in exchange for a cash payment equal to $81.50 per share (without interest) subject to any required withholding of taxes minus the per share exercise price of the option. In connection with the Merger, vesting of the option was accelerated and the option became fully vested and exercisable effective immediately prior to the effective time of the Merger. Read SEC document
September 28, 2016 Filed Sep 30, 2016 17:45 UTC	MEDIVATION, INC. MDVN · Entity 181987	Disposition to issuerNon-Qualified Stock Option (right to buy) · Derivative	310,000	Not disclosed Strike: $27.43	Not disclosed	Disclosure SEC source: 0001209191-16-143381 · doc4.xml · derivative · entry 8 Hung David · CIK 0001310880 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 310,000 shares Expires 2022-12-17 F3 · price: This option was cancelled in the Merger in exchange for a cash payment equal to $81.50 per share (without interest) subject to any required withholding of taxes minus the per share exercise price of the option. In connection with the Merger, vesting of the option was accelerated and the option became fully vested and exercisable effective immediately prior to the effective time of the Merger. F3 · derivative.exercise_date: This option was cancelled in the Merger in exchange for a cash payment equal to $81.50 per share (without interest) subject to any required withholding of taxes minus the per share exercise price of the option. In connection with the Merger, vesting of the option was accelerated and the option became fully vested and exercisable effective immediately prior to the effective time of the Merger. Read SEC document
September 28, 2016 Filed Sep 30, 2016 17:45 UTC	MEDIVATION, INC. MDVN · Entity 181987	Disposition to issuerNon-Qualified Stock Option (right to buy) · Derivative	400,000	Not disclosed Strike: $3.37	Not disclosed	Disclosure SEC source: 0001209191-16-143381 · doc4.xml · derivative · entry 7 Hung David · CIK 0001310880 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 400,000 shares Expires 2020-12-15 F3 · price: This option was cancelled in the Merger in exchange for a cash payment equal to $81.50 per share (without interest) subject to any required withholding of taxes minus the per share exercise price of the option. In connection with the Merger, vesting of the option was accelerated and the option became fully vested and exercisable effective immediately prior to the effective time of the Merger. F3 · derivative.exercise_date: This option was cancelled in the Merger in exchange for a cash payment equal to $81.50 per share (without interest) subject to any required withholding of taxes minus the per share exercise price of the option. In connection with the Merger, vesting of the option was accelerated and the option became fully vested and exercisable effective immediately prior to the effective time of the Merger. Read SEC document
September 28, 2016 Filed Sep 30, 2016 17:45 UTC	MEDIVATION, INC. MDVN · Entity 181987	Disposition to issuerNon-Qualified Stock Option (right to buy) · Derivative	593,750	Not disclosed Strike: $8.64	Not disclosed	Disclosure SEC source: 0001209191-16-143381 · doc4.xml · derivative · entry 6 Hung David · CIK 0001310880 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 593,750 shares Expires 2019-12-15 F3 · price: This option was cancelled in the Merger in exchange for a cash payment equal to $81.50 per share (without interest) subject to any required withholding of taxes minus the per share exercise price of the option. In connection with the Merger, vesting of the option was accelerated and the option became fully vested and exercisable effective immediately prior to the effective time of the Merger. F3 · derivative.exercise_date: This option was cancelled in the Merger in exchange for a cash payment equal to $81.50 per share (without interest) subject to any required withholding of taxes minus the per share exercise price of the option. In connection with the Merger, vesting of the option was accelerated and the option became fully vested and exercisable effective immediately prior to the effective time of the Merger. Read SEC document
September 28, 2016 Filed Sep 30, 2016 17:45 UTC	MEDIVATION, INC. MDVN · Entity 181987	Disposition to issuerNon-Qualified Stock Option (right to buy) · Derivative	366,194	Not disclosed Strike: $4.69	Not disclosed	Disclosure SEC source: 0001209191-16-143381 · doc4.xml · derivative · entry 5 Hung David · CIK 0001310880 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 366,194 shares Expires 2018-10-31 F3 · price: This option was cancelled in the Merger in exchange for a cash payment equal to $81.50 per share (without interest) subject to any required withholding of taxes minus the per share exercise price of the option. In connection with the Merger, vesting of the option was accelerated and the option became fully vested and exercisable effective immediately prior to the effective time of the Merger. F3 · derivative.exercise_date: This option was cancelled in the Merger in exchange for a cash payment equal to $81.50 per share (without interest) subject to any required withholding of taxes minus the per share exercise price of the option. In connection with the Merger, vesting of the option was accelerated and the option became fully vested and exercisable effective immediately prior to the effective time of the Merger. Read SEC document
September 28, 2016 Filed Sep 30, 2016 17:45 UTC	MEDIVATION, INC. MDVN · Entity 181987	Disposition to issuerNon-Qualified Stock Option (right to buy) · Derivative	448,888	Not disclosed Strike: $5.29	Not disclosed	Disclosure SEC source: 0001209191-16-143381 · doc4.xml · derivative · entry 4 Hung David · CIK 0001310880 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 448,888 shares Expires 2017-10-01 F3 · price: This option was cancelled in the Merger in exchange for a cash payment equal to $81.50 per share (without interest) subject to any required withholding of taxes minus the per share exercise price of the option. In connection with the Merger, vesting of the option was accelerated and the option became fully vested and exercisable effective immediately prior to the effective time of the Merger. F3 · derivative.exercise_date: This option was cancelled in the Merger in exchange for a cash payment equal to $81.50 per share (without interest) subject to any required withholding of taxes minus the per share exercise price of the option. In connection with the Merger, vesting of the option was accelerated and the option became fully vested and exercisable effective immediately prior to the effective time of the Merger. Read SEC document
September 28, 2016 Filed Sep 30, 2016 17:45 UTC	MEDIVATION, INC. MDVN · Entity 181987	OtherCommon Stock	145,120	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-16-143381 · doc4.xml · nonDerivative · entry 3 Hung David · CIK 0001310880 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 0 F1 · kind: Disposed of pursuant to an Agreement and Plan of Merger (the "Merger Agreement"), dated August 20, 2016, among the Issuer, Pfizer Inc., a Delaware corporation ("Parent"), and Montreal, Inc., a Delaware corporation and a wholly-owned subsidiary of Parent ("Purchaser"), in exchange for a cash consideration of $81.50 per share (without interest) subject to any required withholding of taxes. Pursuant to the Merger Agreement, the Purchaser merged with and into the Issuer, with the Issuer surviving as a wholly-owned subsidiary of Parent (the "Merger"). In connection with the Merger, Purchaser offered to purchase all of the outstanding shares of common stock, par value $0.01 per share of the Issuer, at a price of $81.50 per share, net to the seller in cash (without interest) but subject to any required withholding of taxes, upon the terms and conditions set forth in the offer to purchase dated August 30, 2016, and in the related letter of transmittal. F1 · price: Disposed of pursuant to an Agreement and Plan of Merger (the "Merger Agreement"), dated August 20, 2016, among the Issuer, Pfizer Inc., a Delaware corporation ("Parent"), and Montreal, Inc., a Delaware corporation and a wholly-owned subsidiary of Parent ("Purchaser"), in exchange for a cash consideration of $81.50 per share (without interest) subject to any required withholding of taxes. Pursuant to the Merger Agreement, the Purchaser merged with and into the Issuer, with the Issuer surviving as a wholly-owned subsidiary of Parent (the "Merger"). In connection with the Merger, Purchaser offered to purchase all of the outstanding shares of common stock, par value $0.01 per share of the Issuer, at a price of $81.50 per share, net to the seller in cash (without interest) but subject to any required withholding of taxes, upon the terms and conditions set forth in the offer to purchase dated August 30, 2016, and in the related letter of transmittal. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.